scholarly journals Hippo signalling in the G2/M cell cycle phase: Lessons learned from the yeast MEN and SIN pathways

2012 ◽  
Vol 23 (7) ◽  
pp. 794-802 ◽  
Author(s):  
Alexander Hergovich ◽  
Brian A. Hemmings
Keyword(s):  
Cell Cycle ◽  
Cell Cycle Phase ◽  
Lessons Learned ◽  
Cycle Phase ◽  
M Cell ◽  
Hippo Signalling

scholarly journals Enrichment of G2/M cell cycle phase in human pluripotent stem cells enhances HDR-mediated gene repair with customizable endonucleases

2016 ◽  
Vol 6 (1) ◽  
Author(s):  
Diane Yang ◽  
Marissa A Scavuzzo ◽  
Jolanta Chmielowiec ◽  
Robert Sharp ◽  
Aleksandar Bajic ◽  
...  
Keyword(s):  
Cell Cycle ◽  
Stem Cells ◽  
Pluripotent Stem Cells ◽  
Human Pluripotent Stem Cells ◽  
Cell Cycle Phase ◽  
Cycle Phase ◽  
Gene Repair ◽  
M Cell

scholarly journals Combination of Abemaciclib following Eribulin Overcomes Palbociclib-Resistant Breast Cancer by Inhibiting the G2/M Cell Cycle Phase

Cancers ◽  
2022 ◽  
Vol 14 (1) ◽  
pp. 210
Author(s):  
Kamal Pandey ◽  
Nar Bahadur Katuwal ◽  
Nahee Park ◽  
Jin Hur ◽  
Young Bin Cho ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cell Cycle ◽  
Cytotoxic Chemotherapy ◽  
Cell Cycle Phase ◽  
Cycle Phase ◽  
Preclinical Model ◽  
M Cell ◽  
Proliferating Cells ◽  
Positive Breast Cancer

Breast cancer remains a leading cancer burden among women worldwide. Acquired resistance of cyclin-dependent kinase (CDK) 4/6 inhibitors occurs in almost all hormone receptor (HR)-positive subtype cases, comprising 70% of breast cancers, although CDK4/6 inhibitors combined with endocrine therapy are highly effective. CDK4/6 inhibitors are not expected to cooperate with cytotoxic chemotherapy based on the basic cytotoxic chemotherapy mode of action that inhibits rapidly proliferating cells. The palbociclib-resistant preclinical model developed in the current study investigated whether the combination of abemaciclib, CDK4/6 inhibitor with eribulin, an antimitotic chemotherapy could be a strategy to overcome palbociclib-resistant HR-positive breast cancer. The current study demonstrated that sequential abemaciclib treatment following eribulin synergistically suppressed CDK4/6 inhibitor-resistant cells by inhibiting the G2/M cell cycle phase more effectively. The current study showed the significant association of the pole-like kinase 1 (PLK1) level and palbociclib resistance. Moreover, the cumulative PLK1 inhibition in the G2/M phase by each eribulin or abemaciclib proved to be a mechanism of the synergistic effect. The synergistic antitumor effect was also supported by in vivo study. The sequential combination of abemaciclib following eribulin merits further clinical trials to overcome resistance to CDK4/6 inhibitors in HR-positive breast cancer.

ALG-2 knockdown in HeLa cells results in G2/M cell cycle phase accumulation and cell death

2009 ◽  
Vol 378 (1) ◽  
pp. 145-148 ◽  
Author(s):  
Berit R. Høj ◽  
Jonas M. la Cour ◽  
Jens Mollerup ◽  
Martin W. Berchtold
Keyword(s):  
Cell Cycle ◽  
Cell Death ◽  
Hela Cells ◽  
Cell Cycle Phase ◽  
Cycle Phase ◽  
M Cell ◽  
Phase Accumulation

Growth and cell cycle phase composition of fibroblasts in the reconstituted dermis model.

1990 ◽  
Vol 52 (5) ◽  
pp. 986-992
Author(s):  
Takeshi KONO ◽  
Tsukasa TANII ◽  
Masayoshi FURUKAWA ◽  
Nobuyuki MIZUNO ◽  
Shoji TANIGUCHI ◽  
...  
Keyword(s):  
Cell Cycle ◽  
Phase Composition ◽  
Cell Cycle Phase ◽  
Cycle Phase
Sign in / Sign up

Export Citation Format

Share Document